Literature DB >> 34330182

Global, Regional, and National Incidence and Year Lived with Disability for Benign Prostatic Hyperplasia from 1990 to 2019.

Xiao-Feng Xu1,2, Guo-Xiong Liu1, Ya-Shou Guo1, Hai-Yun Zhu2, Da-Lin He3, Xi-Min Qiao1,2, Xu-Hui Li2,4.   

Abstract

The objective of this study is to provide comprehensive and up-to-date estimates on the disease burden of BPH in 204 countries and territories between 1990 and 2019. Data about incidence, year lived with disability (YLD), and their age-standardized rates (ASRs) for 21 regions, 5 Socio-demographic Index (SDI) quintiles, 204 countries and territories, and 12 age categories from 1990 to 2019 were obtained from the Global Burden of Disease 2019 study. Estimated annual percentage changes (EAPCs) of the ASRs and the associations between SDI and the ASRs were estimated. The effects of population growth, population aging, and age-specific rate on the changes in the absolute numbers of incidence and YLD were quantified. Globally, there were 11.26 million (95% uncertainty interval [UI]: 8.79, 14.46) new cases and 1.86 million (95%UI: 1.13, 2.78) YLD due to BPH in 2019. The global ASRs of incidence (EAPC: -0.031, 95% CI: -0.050, -0.012) and YLD (EAPC: -0.058, 95% CI: -0.084, -0.031) decreased slightly from 1990 to 2019, whereas the absolute numbers increased dramatically from 1990 (incidence by 105.7% and YLD by 110.6%), mainly driven by the population growth (53.5% for incidence and 54.4% for YLD) and population aging (55.7% for incidence and 63.2% for YLD). The burden of BPH varied markedly among different regions, socioeconomic status, and countries. As the population is growing and aging, great efforts are required to develop effective prevention, treatment and management strategies to meet the high and increasing burden of BPH worldwide.

Entities:  

Keywords:  benign prostatic hyperplasia; disease burden; incidence; year lived with disability

Year:  2021        PMID: 34330182     DOI: 10.1177/15579883211036786

Source DB:  PubMed          Journal:  Am J Mens Health        ISSN: 1557-9883


  5 in total

1.  The role of FASL, BCL-2 and BAX polymorphisms in brazilian patients with prostate cancer and benign prostatic hyperplasia.

Authors:  Gabriela Kniphoff da Silva Lawisch; Vanderlei Biolchi; Gabriela Kaufmann; Gabriela Nicolai; Eduarda Capitaneo; Thais Regina Rosembach; Janaina Zang; Ilma Simoni Brum; José Artur Bogo Chies
Journal:  Mol Biol Rep       Date:  2022-08-21       Impact factor: 2.742

2.  Using Haemocoagulase Agkistrodon in Patients Undergoing Transurethral Plasmakinetic Resection of the Prostate: A Pilot, Real-World, and Propensity Score-Matched Study.

Authors:  Cong Zhu; Lan Yang; Hao Zi; Bing-Hui Li; Qiao Huang; Meng-Xin Lu; Xiao-Dong Li; Xuan-Yi Ren; Hua Tao; Hankun Hu; Xian-Tao Zeng
Journal:  Biomed Res Int       Date:  2022-06-22       Impact factor: 3.246

3.  Alterations of gut microbiota diversity, composition and metabonomics in testosterone-induced benign prostatic hyperplasia rats.

Authors:  Lu-Yao Li; Jie Han; Lan Wu; Cheng Fang; Wei-Guang Li; Jia-Min Gu; Tong Deng; Chang-Jiang Qin; Jia-Yan Nie; Xian-Tao Zeng
Journal:  Mil Med Res       Date:  2022-03-28

4.  Comparison of the Efficacy and Safety of Minimally Invasive Simple Prostatectomy and Endoscopic Enucleation of Prostate for Large Benign Prostatic Hyperplasia.

Authors:  Jinze Li; Dehong Cao; Chunyang Meng; Zhongyou Xia; Lei Peng; Yunxiang Li; Qiang Wei
Journal:  Front Med (Lausanne)       Date:  2021-11-05

Review 5.  Phloretin in Benign Prostate Hyperplasia and Prostate Cancer: A Contemporary Systematic Review.

Authors:  Che-Hsueh Yang; Yen-Chuan Ou; Chi-Chien Lin; Yi-Sheng Lin; Min-Che Tung; Chia-Cheng Yu; Jen-Tai Lin; Chen-Yueh Wen
Journal:  Life (Basel)       Date:  2022-07-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.